Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial

This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor. Steroids are the gold standard post-surgery treatment to reduce swelling (edema) at the surgical site to reduce neurological symptoms. Although, corticosteroids reduce edema, they have side effects including high blood sugar, high blood pressure, and can impair wound healing. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response. It also wor

Trial Details

NCT ID

NCT06132685

Phase

PHASE2

Sponsor

Emory University

Status

RECRUITING

Cancer Type

Brain Cancer

Interventions

• Biospecimen Collection
• Computed Tomography
• Dexamethasone
• Magnetic Resonance Imaging
• Questionnaire Administration

Locations (sample)

• Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

• Patients with radiographic findings consistent with either HGG, LGG, Meningioma, or brain metastasis
• Age equal to or above 18

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →